Search

Your search keyword '"Quest, G"' showing total 2 results
Start Over Author "Quest, G" Database OAIster
2 results on '"Quest, G"'

1. Development of a distributed international patient data registry for hairy cell leukemia

Author

Andritsos, LA, Anghelina, M, Neal, J, Blachly, JS, Mathur, P, Lele, O, Dearden, C, Iyengar, S, Cross, M, Zent, CS, Rogers, KA, Epperla, N, Lozanski, G, Oakes, CC, Kraut, E, Ruppert, AS, Zhao, Q, Bhat, SA, Forconi, F, Banerji, V, Handunnetti, S, Tam, CS, Seymour, JF, Else, M, Kreitman, RJ, Saven, A, Call, T, Parikh, SA, Ravandi, F, Johnston, JB, Tiacci, E, Troussard, X, Tallman, MS, Dietrich, S, Tadmor, T, Gozzetti, A, Zinzani, PL, Robak, T, Quest, G, Demeter, J, Rai, K, Fernandez, SA, Grever, M, Andritsos, LA, Anghelina, M, Neal, J, Blachly, JS, Mathur, P, Lele, O, Dearden, C, Iyengar, S, Cross, M, Zent, CS, Rogers, KA, Epperla, N, Lozanski, G, Oakes, CC, Kraut, E, Ruppert, AS, Zhao, Q, Bhat, SA, Forconi, F, Banerji, V, Handunnetti, S, Tam, CS, Seymour, JF, Else, M, Kreitman, RJ, Saven, A, Call, T, Parikh, SA, Ravandi, F, Johnston, JB, Tiacci, E, Troussard, X, Tallman, MS, Dietrich, S, Tadmor, T, Gozzetti, A, Zinzani, PL, Robak, T, Quest, G, Demeter, J, Rai, K, Fernandez, SA, and Grever, M

Abstract

Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder, comprising only 2% of all leukemias. The Hairy Cell Leukemia Foundation (HCLF) has developed a patient data registry to enable investigators to better study the clinical features, treatment outcomes, and complications of patients with HCL. This system utilizes a centralized registry architecture. Patients are enrolled at HCL Centers of Excellence (COE) or via a web-based portal. All data are de-identified, which reduces regulatory burden and increases opportunities for data access and re-use. To date, 579 patients have been enrolled in the registry. Efforts are underway to engage additional COE's to expand access to patients across the globe. This international PDR will enable researchers to study outcomes in HCL in ways not previously possible due to the rarity of the disease and will serve as a platform for future prospective research.

Published
2022

2. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Author

Ravandi, F, Kreitman, RJ, Tiacci, E, Andritsos, L, Banerji, V, Barrientos, JC, Bhat, SA, Blachly, JS, Broccoli, A, Call, T, Chihara, D, Dearden, C, Demeter, J, Dietrich, S, Else, M, Epperla, N, Falini, B, Forconi, F, Gladstone, DE, Gozzetti, A, Iyengar, S, Johnston, JB, Jorgensen, J, Juliusson, G, Lauria, F, Lozanski, G, Parikh, SA, Park, JH, Polliack, A, Quest, G, Robak, T, Rogers, KA, Saven, A, Seymour, JF, Tadmor, T, Tallman, MS, Tam, CS, Thompson, PA, Troussard, X, Zent, CS, Zenz, T, Zinzani, PL, Woermann, B, Rai, K, Grever, M, Ravandi, F, Kreitman, RJ, Tiacci, E, Andritsos, L, Banerji, V, Barrientos, JC, Bhat, SA, Blachly, JS, Broccoli, A, Call, T, Chihara, D, Dearden, C, Demeter, J, Dietrich, S, Else, M, Epperla, N, Falini, B, Forconi, F, Gladstone, DE, Gozzetti, A, Iyengar, S, Johnston, JB, Jorgensen, J, Juliusson, G, Lauria, F, Lozanski, G, Parikh, SA, Park, JH, Polliack, A, Quest, G, Robak, T, Rogers, KA, Saven, A, Seymour, JF, Tadmor, T, Tallman, MS, Tam, CS, Thompson, PA, Troussard, X, Zent, CS, Zenz, T, Zinzani, PL, Woermann, B, Rai, K, and Grever, M

Abstract

A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). However, due to the indolent nature of the disease as well as reports suggesting long-term survival in patients treated with a single course of a nucleoside analog albeit without evidence of cure, the merits of detection of MRD and attempts to eradicate it have been debated. Studies utilizing novel strategies in the relapse setting have demonstrated the utility of achieving CR with undetectable MRD (uMRD) in prolonging the duration of remission. Several assays including immunohistochemical analysis of bone marrow specimens, multi-parameter flow cytometry and molecular assays to detect the mutant BRAF V600E gene or the consensus primer for the immunoglobulin heavy chain gene (IGH) rearrangement have been utilized with few comparative studies. Here we provide a consensus report on the available data, the potential merits of MRD assessment in the front-line and relapse settings and recommendations on future role of MRD assessment in HCL.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results